288 related articles for article (PubMed ID: 34697111)
1. Prospective, multicentre, randomised controlled trial comparing the seroclearance of HBsAg between combination therapy of peg-interferon alpha and tenofovir with tenofovir monotherapy in nucleos(t)ide analogue-experienced patients with HBV-related liver fibrosis: a study protocol.
Zhu S; Wu L; Mei Y; Liu Z; Lin L; Yuan J; Li J; Li X; Peng L
BMJ Open; 2021 Oct; 11(10):e049104. PubMed ID: 34697111
[TBL] [Abstract][Full Text] [Related]
2. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy.
Bazinet M; Pântea V; Placinta G; Moscalu I; Cebotarescu V; Cojuhari L; Jimbei P; Iarovoi L; Smesnoi V; Musteata T; Jucov A; Dittmer U; Krawczyk A; Vaillant A
Gastroenterology; 2020 Jun; 158(8):2180-2194. PubMed ID: 32147484
[TBL] [Abstract][Full Text] [Related]
4. Effect of Pegylated Interferon Plus Tenofovir Combination on Higher Hepatitis B Surface Antigen Loss in Treatment-naive Patients With Hepatitis B e Antigen -positive Chronic Hepatitis B: A Real-world Experience.
Hu C; Song Y; Tang C; Li M; Liu J; Liu J; Liao M; Zhou F; Zhang YY; Zhou Y
Clin Ther; 2021 Mar; 43(3):572-581.e3. PubMed ID: 33516527
[TBL] [Abstract][Full Text] [Related]
5. Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial.
de Niet A; Jansen L; Stelma F; Willemse SB; Kuiken SD; Weijer S; van Nieuwkerk CMJ; Zaaijer HL; Molenkamp R; Takkenberg RB; Koot M; Verheij J; Beuers U; Reesink HW
Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):576-584. PubMed ID: 28522204
[TBL] [Abstract][Full Text] [Related]
6. Add-on pegylated interferon augments hepatitis B surface antigen clearance
Wu FP; Yang Y; Li M; Liu YX; Li YP; Wang WJ; Shi JJ; Zhang X; Jia XL; Dang SS
World J Gastroenterol; 2020 Apr; 26(13):1525-1539. PubMed ID: 32308352
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled trial of pegylated interferon-alpha with tenofovir disoproxil fumarate for hepatitis B e antigen-negative chronic hepatitis B: A 48-week follow-up study.
Bahardoust M; Mokhtare M; Barati M; Bagheri-Hosseinabadi Z; Karimi Behnagh A; Keyvani H; Agah S
J Infect Chemother; 2020 Dec; 26(12):1265-1271. PubMed ID: 32762882
[TBL] [Abstract][Full Text] [Related]
8. The expression of interleukin-1β in patients with chronic hepatitis B treated with pegylated-interferon-alpha combined with tenofovir disoproxil fumarate and monotherapy.
Hu X; Luo H; Tan G; Li Y; Qin B
BMC Gastroenterol; 2023 May; 23(1):163. PubMed ID: 37208599
[TBL] [Abstract][Full Text] [Related]
9. Peg-interferon alpha add-on Tenofovir disoproxil fumarate achieved more HBsAg loss in HBeAg-positive chronic hepatitis B naïve patients.
Li J; Qu L; Sun X; Liu Y; Gong Q; Yu D; Zhang D; Jiang J; Chen J; Wei D; Han Y; Gao Y; Zhang Q; She W; Chen L; Zhang J; Zhang X
J Viral Hepat; 2021 Oct; 28(10):1381-1391. PubMed ID: 34228855
[TBL] [Abstract][Full Text] [Related]
10. HBsAg clearance in chronic hepatitis B patients with add-on pegylated interferon alfa-2a to ongoing tenofovir treatment: A randomized controlled study.
Al Ashgar H; Peedikayil MC; Al Quaiz M; Al Sohaibani F; Al Fadda A; Khan MQ; Thoralsson E; Al Thawadi S; Al Jedai A; Al Kahtani K
Saudi J Gastroenterol; 2017; 23(3):190-198. PubMed ID: 28611343
[TBL] [Abstract][Full Text] [Related]
11. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
[TBL] [Abstract][Full Text] [Related]
12. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
13. Entecavir add-on Peg-interferon therapy plays a positive role in reversing hepatic fibrosis in treatment-naïve chronic hepatitis B patients: a prospective and randomized controlled trial.
Yang JM; Chen LP; Wang YJ; Lyu B; Zhao H; Shang ZY; Li J; Fan ZY; Wu SD; Ming X; Li X; Huang SP; Cheng JL
Chin Med J (Engl); 2020 Jul; 133(14):1639-1648. PubMed ID: 32568867
[TBL] [Abstract][Full Text] [Related]
14. HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?
Viganò M; Mangia G; Lampertico P
Liver Int; 2014 Feb; 34 Suppl 1():120-6. PubMed ID: 24373088
[TBL] [Abstract][Full Text] [Related]
15. Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B.
Marcellin P; Ahn SH; Chuang WL; Hui AJ; Tabak F; Mehta R; Petersen J; Lee CM; Ma X; Caruntu FA; Tak WY; Elkhashab M; Lin L; Wu G; Martins EB; Charuworn P; Yee LJ; Lim SG; Foster GR; Fung S; Morano L; Samuel D; Agarwal K; Idilman R; Strasser SI; Buti M; Gaeta GB; Papatheodoridis G; Flisiak R; Chan HL
Aliment Pharmacol Ther; 2016 Nov; 44(9):957-966. PubMed ID: 27629859
[TBL] [Abstract][Full Text] [Related]
16. Peg-interferon and nucleos(t)ide analogue combination at inception of antiviral therapy improves both anti-HBV efficacy and long-term survival among HBV DNA-positive hepatocellular carcinoma patients after hepatectomy/ablation.
Qi W; Zhang Q; Xu Y; Wang X; Yu F; Zhang Y; Zhao P; Guo H; Zhou C; Wang Z; Sun Y; Liu L; Xuan W; Wang J
J Viral Hepat; 2020 Apr; 27(4):387-396. PubMed ID: 31755220
[TBL] [Abstract][Full Text] [Related]
17. Pegylated interferon-α-2b combined with tenofovir disoproxil fumarate, granulocyte-macrophage colony-stimulating factor, and hepatitis B vaccine treatment for naïve HBeAg-positive chronic hepatitis B patients: A prospective, multicenter, randomized controlled study.
Lian J; Kuang W; Jia H; Lu Y; Zhang X; Ye C; Gu J; Lv Y; Yu J; Zhang Y; Lu X; Zhao Y; Yang D; Wang K; Zhao P; Yu Y; Bai L; Zhang J; Zhang X; Yang Y
J Med Virol; 2022 Nov; 94(11):5475-5483. PubMed ID: 35836102
[TBL] [Abstract][Full Text] [Related]
18. Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON).
Chi H; Hansen BE; Guo S; Zhang NP; Qi X; Chen L; Guo Q; Arends P; Wang JY; Verhey E; de Knegt RJ; Xie Q; Janssen HLA
J Infect Dis; 2017 Apr; 215(7):1085-1093. PubMed ID: 28329061
[TBL] [Abstract][Full Text] [Related]
19. Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients.
Jung SK; Kim KA; Ha SY; Lee HK; Kim YD; Lee BH; Paik WH; Kim JW; Bae WK; Kim NH; Lee JS; Jwa YJ
Clin Mol Hepatol; 2015 Mar; 21(1):41-8. PubMed ID: 25834801
[TBL] [Abstract][Full Text] [Related]
20. Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B.
Marcellin P; Ahn SH; Ma X; Caruntu FA; Tak WY; Elkashab M; Chuang WL; Lim SG; Tabak F; Mehta R; Petersen J; Foster GR; Lou L; Martins EB; Dinh P; Lin L; Corsa A; Charuworn P; Subramanian GM; Reiser H; Reesink HW; Fung S; Strasser SI; Trinh H; Buti M; Gaeta GB; Hui AJ; Papatheodoridis G; Flisiak R; Chan HL;
Gastroenterology; 2016 Jan; 150(1):134-144.e10. PubMed ID: 26453773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]